There is no single best CAR-T hospital for every patient. The practical starting point is to identify the commercially approved pathway that a treating hospital is willing to assess, then compare its current capability, records process, safety support and travel requirements in writing.
Quick answer: China has nine NMPA-approved CAR-T products as of July 2026, but a product list, a hospital ranking or a price reference cannot establish whether CAR-T is suitable for an individual. That decision belongs to the treating hospital and specialist after reviewing the case.
Important: CAR-T is not an emergency travel route. If a patient has urgent symptoms or clinical deterioration, contact the current treating team or local emergency services first. Do not wait for a hospital reply, an insurer, a visa process or a China Care message.
Table of Contents
Who This Guide Is For
This guide is designed for international patients and families who are researching a planned CAR-T pathway in China and want to make a more useful first shortlist. It can help if you:
- have a blood-cancer diagnosis and want to understand which questions a CAR-T hospital must answer;
- already know a hospital, city, department or specialist you want to approach;
- have been told that CAR-T may be discussed and need to prepare records before a hospital review;
- are comparing commercial CAR-T products with a possible clinical-trial route; or
- are planning travel and need to understand why hospital confirmation should come before non-refundable bookings.
It is not a clinical recommendation, a doctor ranking, a promise that a hospital will accept a case, or a substitute for advice from the patient’s treating hematology or oncology team. For an overview of the treatment itself, start with CAR-T Cell Therapy in China. For a cost framework, read CAR-T Cell Therapy Cost in China vs USA.
Start With the Pathway, Not a Ranking
A search result may describe a hospital as leading, international or experienced. Those labels are not enough to decide where a person should be treated. The useful first question is narrower: which treating team is prepared to review this particular diagnosis, treatment history and current condition for an available pathway?
China has nine NMPA-approved CAR-T products as of July 2026. They cover different targets and labelled indications, including CD19, BCMA and CLDN18.2 pathways. Approval does not mean that every product is appropriate for every disease, that every hospital administers every product, or that a product is currently available at a particular site. The treating hospital decides whether a commercial product, another treatment approach, further assessment or no China-based route is appropriate.
For a first-time overseas patient, a commercially approved CAR-T pathway is usually the realistic route to investigate first. It is an established treatment-access pathway with a hospital-led assessment, product selection and admission decision. It should not be confused with a trial vacancy or a product mentioned in a research paper.
Commercial CAR-T and Clinical Trials Are Different Routes
Clinical trials are important to cancer research, but they are not a standard booking channel for overseas medical travel. A trial must have an open protocol, the right diagnosis and eligibility criteria, a research team willing to assess the case, and an available place. Eligibility on paper does not guarantee enrollment.
Since May 2026, investigator-initiated CAR-T trials are limited to public hospitals in China. For an international patient who has not previously received care in China, places may be particularly difficult to access because recruitment often prioritises existing patients and domestic referral networks. A trial should therefore be presented as a possible, protocol-led exception rather than a lower-cost default plan.
| Route | What it means | What the hospital still decides | Useful first action |
|---|---|---|---|
| Commercial CAR-T | An NMPA-approved product may be assessed within its labelled pathway | Diagnosis, indication, product, availability, admission, timing and medical risk | Prepare records and ask a treating hospital whether it will review the case |
| Clinical trial | An investigational protocol may be open at a public research hospital | Trial match, eligibility, seat availability, research-team acceptance and all treatment decisions | Treat the trial as uncertain; do not book travel around it |
| Further assessment or another treatment route | CAR-T may not be the next appropriate step | Full clinical plan and whether another approach is safer or more suitable | Continue with the current treating team while seeking hospital-led review |
The ClinicalTrials.gov China CAR-T search can help readers understand the research landscape. It cannot tell a patient that a specific trial is accessible, suitable or currently recruiting them.
How to Compare Hospitals in China
A hospital comparison is most useful when it focuses on verifiable operational questions rather than on marketing claims. Use the checklist below for every facility you research, whether it is in Beijing, Shanghai, Hainan or another city.
| What to verify | Why it matters | Who can confirm it |
|---|---|---|
| Relevant department and diagnosis pathway | CAR-T assessment is disease- and treatment-history-specific | The hospital or specialist team |
| Current commercial-product pathway | Products, indications and local availability may differ | The treating hospital |
| Records format and review process | The team may need pathology, imaging, laboratory results and treatment history in a specific format | The treating hospital |
| Admission and monitoring arrangements | Inpatient planning, intensive-care escalation and discharge rules vary by case and institution | The treating hospital |
| Language and document arrangements | Do not assume English documentation or interpreter availability | The hospital, confirmed in writing |
| Cost components and payment route | Product, admission, tests, medicines and supportive care may be quoted separately | The hospital’s written estimate |
| Travel documentation requirements | An invitation letter, if needed, can only come from the treating hospital | The hospital and the relevant immigration authority |
A useful shortlisting process does not rely on one statistic or a headline. It identifies what is known, what remains unconfirmed and which institution is actually willing to review the records. You can research facilities through the China Care hospital directory and city pages for Beijing, Shanghai and Hainan Lecheng.
Hospitals to Research Further
The facilities below are research starting points, not a ranked recommendation or a statement that they will accept a particular case. Confirm current services, records requirements and access directly with the relevant treating institution.
1. Ruijin Hospital (Shanghai) – Best for Commercial Excellence
Ruijin Hospital is a major Shanghai academic hospital with hematology and oncology capabilities. It may be relevant for readers who want to research a large public-hospital pathway in Shanghai. Start with the Shanghai government’s international hospital listing for Ruijin, then ask the hospital whether it is willing to review the specific diagnosis and treatment history.
Before treating a listing as a practical option, confirm the department, the current commercial-product route, the record-review process, expected admission sequence, language arrangements and the written cost estimate. Public-hospital research activity does not make trial enrollment automatic.
2. GoBroad Healthcare Group (Beijing & Shanghai) – Best for Patient Logistics
Beijing GoBroad Hospital is a private hospital readers may research when they are exploring commercially approved CAR-T for lymphoma or myeloma. Its current role must be described carefully: a private hospital may assess and administer an agreed commercially approved pathway, but it is not the route for investigator-initiated, investigational dual-target or autoimmune CAR-T trials. Those trial pathways are not a standard option for overseas patients.
Use the GoBroad hospital profile as a starting point, then obtain current information from the hospital. Do not assume a past social-media case, a target list or a generic international-patient claim establishes today’s availability for a new case.
3. Peking Union Medical College Hospital (Beijing) – Best for Complex Cases
Peking Union Medical College Hospital is a large Beijing academic institution that readers may research for complex hematology or oncology care. Its official English-language site provides institutional background. It cannot replace a treating-team review of the individual case.
For any hospital under consideration, the important questions remain the same: which team will review the records, whether there is an appropriate current pathway, what additional tests are required, and what is needed before a travel decision is made.
Special Mention: Boao Lecheng (Hainan Island)
The Boao Lecheng International Medical Tourism Pilot Zone is a special economic zone offering zero-tariff access to innovative therapies approved abroad but not yet widely available in mainland China — including therapies like FDA-approved Abecma (idecabtagene vicleucel), which showed a 73% ORR in the KarMMa trial. For patients seeking CAR-T + PD-1 combination protocols or experimental therapies, Boao Lecheng provides a unique regulatory pathway. Mayo Clinic’s clinical overview of CAR-T notes that combination immunotherapy approaches remain an active area of investigation — precisely the category of trials accelerated through the Boao Lecheng zone.
The Decision Gap: Why a List Cannot Choose for You
The choice between hospitals cannot safely be made from price, a city, a product target or a search ranking. The decision turns on details a treating team must assess, including:
- the confirmed pathology and current disease status;
- previous lines of therapy and response history;
- whether the patient falls within a product’s approved indication;
- current blood counts, organ function, infection status and other medical factors;
- whether bridging treatment, additional tests or a different route may be needed;
- the hospital’s own current capacity, records process and travel requirements; and
- whether the patient can safely plan travel and post-discharge follow-up.
This is why a hospital list is a research tool, not a treatment recommendation. A patient can independently compare official hospital sources and request a review. If the practical question is which facilities are worth approaching first, optional non-clinical coordination can help organise the approach, but it does not replace the hospital’s clinical judgment.
A Practical Records and Questions Checklist
Before asking a hospital to review a case, prepare a clear, dated file set. The hospital may request different or additional material.
Records often requested for a planned hematology review
- pathology report and, if available, relevant pathology materials as requested by the hospital;
- PET-CT, CT, MRI or other imaging reports and available image files;
- diagnosis summary, staging information and treatment timeline;
- prior chemotherapy, transplant, radiotherapy, targeted therapy and immunotherapy history;
- recent blood tests and other laboratory results;
- current medication list, allergies and infection history;
- treating doctor’s summary, if available; and
- passport and travel details only when a hospital asks for them.
Questions worth asking the hospital
- Will your department review records for this diagnosis and treatment history?
- Which documents, format and language are required before review?
- Is there a commercially approved pathway that the team may consider, or is further assessment needed first?
- What current admission, monitoring and discharge arrangements should a family plan around?
- Which costs will be quoted directly by the hospital, and which are not included?
- If travel documentation is needed, what can the hospital provide after it has accepted the case?
For a patient already considering travel, the CAR-T treatment timeline guide explains why a hospital-confirmed sequence matters before flights or accommodation are booked.
Common Mistakes When Comparing CAR-T Hospitals
- Treating “best” as a clinical recommendation. A list cannot account for diagnosis, prior therapy, product indication or current hospital capacity.
- Planning around a trial before an open protocol is confirmed. Trial enrollment is limited and not guaranteed.
- Assuming a product target means the product is appropriate. Target, indication and patient suitability are different questions.
- Booking non-refundable travel before written hospital confirmation. A case review, additional tests or timing changes can alter the plan.
- Using a product price as an all-in estimate. Hospital charges may include separate assessment, tests, admission, medicines and supportive care.
- Assuming a facilitator can issue an invitation letter or decide eligibility. Only the treating hospital can issue its own invitation letter and decide clinical access.
How China Care Can Help With the Practical Route
China Care is a non-clinical coordination service. A family may always contact a hospital independently. China Care’s role, where agreed, is to help organise the practical access and communication steps; it does not diagnose, recommend a product or decide whether a patient is eligible.
If You Already Know the Hospital You Want to Approach
Hospital Access is for one agreed hospital visit when you already know the hospital, city, department or specialist. It covers appointment coordination, hospital confirmation and a visit-preparation checklist. It does not include hospital fees, diagnosis, treatment decisions or a promise that the hospital will accept the case. Review the current Hospital Access service scope before deciding whether it fits.
If You Need Help Deciding Which Facilities to Approach First
Case Coordination is for a complex case where a family needs practical help identifying up to two facilities worth approaching first. It includes case coordination, matching and outreach to up to two facilities, plus a practical next-step summary. Clinical suitability remains the hospital’s decision. See current pricing and service terms for the full scope.
Frequently Asked Questions
Can China Care tell me which CAR-T hospital is medically best for me?
No. A treating hospital and specialist decide clinical suitability, product choice and medical recommendations. China Care can provide non-clinical coordination within an agreed service scope, while you can also contact hospitals independently.
Are clinical trials a cheaper way to obtain CAR-T in China?
No. A trial is not a standard access route or a guaranteed lower-cost option. It depends on an open protocol, research-team assessment and limited enrollment. For first-time overseas patients, commercially approved CAR-T is generally the more realistic pathway to investigate first.
Do all CAR-T hospitals offer all nine approved products?
No. NMPA approval does not mean a product is administered at every hospital or appropriate for every diagnosis. Confirm the current route directly with the treating institution.
Can I book flights as soon as I find a hospital online?
It is safer to wait for written hospital confirmation of the records process, current plan and any travel documentation requirements. The final timing depends on the hospital and the individual case.
Who issues an S1 or S2 visa invitation letter?
Only the treating hospital can issue its own invitation letter after it has decided to do so. China Care does not issue visas or invitation letters, and an invitation letter does not itself guarantee visa issuance.
Are China Care’s prices medical fees?
No. China Care’s published prices are coordination-service fees. Hospital medical charges are separately quoted and collected by the treating hospital.
Need Practical Help Choosing Which Hospitals to Approach?
If you already know your hospital, city, department or specialist, begin with the Hospital Access scope. If the practical problem is deciding which facilities are worth approaching first, review Case Coordination and current pricing.
For independent research, use the hospital directory, the commercial CAR-T overview and the CAR-T cost guide. Any China Care conversation is optional, non-emergency and non-clinical.
References
Mayo Clinic: CAR-T cell therapy overview.
China National Medical Products Administration approval information and relevant product labels.
ClinicalTrials.gov: CAR-T studies in China.
Shanghai government international hospital listing: Ruijin Hospital.
Peking Union Medical College Hospital official English site.
